| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | B61; EFL1; ECKLG; EPLG1; LERK1; LERK-1; TNFAIP4;;Ephrin A1 |
| WB Predicted band size | 24 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human Ephrin A1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于EphrinA1抗体的3篇参考文献示例(注：文献信息为模拟生成，仅供参考)：
1. **"EphrinA1-mediated cell contact regulates vascular sprouting via EphA2 receptor activation"**
*作者：Cheng N. et al.*
*摘要*：研究通过EphrinA1抗体阻断EphA2受体与配体结合，发现其抑制血管内皮细胞的迁移和管状结构形成，揭示了EphrinA1-EphA2信号在血管生成中的关键作用。
2. **"Targeting EphrinA1 with monoclonal antibodies inhibits tumor growth and angiogenesis in murine models"**
*作者：Brantley-Sieders D.M. et al.*
*摘要*：开发了一种靶向EphrinA1的单克隆抗体，证明其通过抑制肿瘤微环境中EphrinA1介导的血管新生和癌细胞侵袭，显著降低小鼠移植瘤的生长速率。
3. **"Structural basis of EphrinA1 recognition by therapeutic antibodies for cancer treatment"**
*作者：Smith J.R. & Pasquale E.B.*
*摘要*：通过晶体学分析揭示EphrinA1抗体与EphrinA1的结合表位，并验证其在体外阻断EphA受体激活的能力，为抗体药物的优化提供结构基础。
如需具体文献，建议在PubMed或Web of Science中检索关键词“EphrinA1 antibody”或“EphrinA1 therapeutic”。
EphrinA1 antibodies are immunological tools designed to target ephrin-A1. a membrane-bound ligand belonging to the ephrin family, which interacts with Eph receptors (EphA subclass). EphrinA1 is a glycosylphosphatidylinositol (GPI)-anchored protein involved in bidirectional cell signaling, regulating processes like cell adhesion, migration, and tissue boundary formation. It plays critical roles in developmental biology, angiogenesis, and neurogenesis, and is implicated in pathological conditions, including cancer metastasis, inflammation, and vascular diseases.
EphrinA1 antibodies are widely used in research to study protein expression, localization, and signaling mechanisms. They enable detection via techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Function-blocking EphrinA1 antibodies help dissect ligand-receptor interactions, particularly in tumor microenvironments where EphrinA1-EphA crosstalk influences cell proliferation and invasion. Conversely, activating antibodies can mimic ligand effects, aiding in pathway activation studies.
These antibodies are vital in exploring therapeutic potentials. For instance, in cancer research, EphrinA1 targeting may inhibit tumor angiogenesis or metastasis. In neurodegenerative studies, they help assess EphrinA1's role in axon guidance and synaptic plasticity. Commercial EphrinA1 antibodies are typically validated for specificity and affinity, with applications spanning basic research, drug discovery, and biomarker development. Their utility underscores the importance of EphrinA1 in both physiological and disease contexts, driving ongoing studies to harness its regulatory pathways for clinical interventions.
×
